This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.75% per year. These returns cover a period from January 1, 1988 through July 7, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Thousand Oaks, CA-based Amgen is one of the biggest biotech companies in the world, with a strong presence in the oncology/hematology, cardiovascular disease, neuroscience, inflammation, bone health and nephrology markets. The company used advances in cellular and molecular biology to develop two of the biotech industry’s earliest and most successful drugs, Epogen (anemia) and Neupogen (white blood cell stimulant). Amgen successfully launched two next-generation products, Aranesp and Neulasta. Meanwhile, the acquisition of Immunex Corporation gave Amgen access to the multi-blockbuster drug, Enbrel. However, all these older drugs are facing declining sales due to biosimilar or branded competition, which is being somewhat offset by its newer blockbuster drugs like Prolia/Xgeva
Compared to Estimates, Amgen (AMGN) Q3 Earnings: A Look at Key Metrics
by Zacks Equity Research
The headline numbers for Amgen (AMGN) give insight into how the company performed in the quarter ended September 2024, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.
Amgen (AMGN) Beats Q3 Earnings Estimates
by Zacks Equity Research
Amgen (AMGN) delivered earnings and revenue surprises of 9.20% and 0.04%, respectively, for the quarter ended September 2024. Do the numbers hold clues to what lies ahead for the stock?
Top Stock Reports for Costco, Coca-Cola & T-Mobile US
by Mark Vickery
Today's Research Daily features new research reports on 16 major stocks, including Costco Wholesale Corporation (COST), The Coca-Cola Company (KO) and T-Mobile US, Inc. (TMUS), as well as a micro-cap stock Preformed Line Products Company (PLPC).
Ahead of Amgen (AMGN) Q3 Earnings: Get Ready With Wall Street Estimates for Key Metrics
by Zacks Equity Research
Besides Wall Street's top -and-bottom-line estimates for Amgen (AMGN), review projections for some of its key metrics to gain a deeper understanding of how the company might have fared during the quarter ended September 2024.
Here is What to Know Beyond Why Amgen Inc. (AMGN) is a Trending Stock
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Kymera Therapeutics, Inc. (KYMR) Expected to Beat Earnings Estimates: What to Know Ahead of Q3 Release
by Zacks Equity Research
Kymera Therapeutics (KYMR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Is Lilly Stock a Portfolio Must Have Ahead of its Q3 Earnings?
by Zacks Equity Research
Investor focus is likely to be on the sales numbers of LLY's tirzepatide medicines Mounjaro and Zepbound.
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the closing of the recent trading day, Amgen (AMGN) stood at $314.90, denoting a -1.49% change from the preceding trading day.
Amgen Gears Up to Report Q3 Earnings: Here's What to Expect
by Zacks Equity Research
Volume growth from AMGN's key drugs like Prolia, Repatha and Evenity, among others, is expected to have been partially offset by biosimilar/generic competition for mature drugs.
Amgen (AMGN) Earnings Expected to Grow: What to Know Ahead of Next Week's Release
by Zacks Equity Research
Amgen (AMGN) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Should You Invest in the VanEck Biotech ETF (BBH)?
by Zacks Equity Research
Sector ETF report for BBH
Why Amgen (AMGN) Dipped More Than Broader Market Today
by Zacks Equity Research
Amgen (AMGN) reachead $316.74 at the closing of the latest trading day, reflecting a -1.53% change compared to its last close.
NVO Stock Falls 5% in a Month: Should Investors Buy Now or Wait?
by Ahan Chakraborty
Despite the current downward trend of Novo Nordisk, it is an excellent stock to buy for long-term gains, driven by the stellar performance of its GLP-1 drugs.
Lilly Loses Around $14B This Week: How to Play LLY Stock
by Kinjel Shah
Investors can buy LLY stock based on its strong overall financial performance and robust drug pipeline.
Amgen (AMGN) Rises As Market Takes a Dip: Key Facts
by Zacks Equity Research
Amgen (AMGN) closed at $325.09 in the latest trading session, marking a +0.14% move from the prior day.
Amgen Inc. (AMGN) is Attracting Investor Attention: Here is What You Should Know
by Zacks Equity Research
Amgen (AMGN) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
Amgen (AMGN) Dips More Than Broader Market: What You Should Know
by Zacks Equity Research
In the latest trading session, Amgen (AMGN) closed at $321.01, marking a -0.43% move from the previous day.
Is iShares Biotechnology ETF (IBB) a Strong ETF Right Now?
by Zacks Equity Research
Smart Beta ETF report for IBB
Amgen (AMGN) Increases Yet Falls Behind Market: What Investors Need to Know
by Zacks Equity Research
Amgen (AMGN) concluded the recent trading session at $319.66, signifying a +0.69% move from its prior day's close.
Why Amgen (AMGN) Dipped More Than Broader Market Today
by Zacks Equity Research
In the most recent trading session, Amgen (AMGN) closed at $317.48, indicating a -0.7% shift from the previous trading day.
Amgen Inc. (AMGN) Is a Trending Stock: Facts to Know Before Betting on It
by Zacks Equity Research
Zacks.com users have recently been watching Amgen (AMGN) quite a bit. Thus, it is worth knowing the facts that could determine the stock's prospects.
Should You Invest in the iShares Biotechnology ETF (IBB)?
by Zacks Equity Research
Sector ETF report for IBB
Amgen (AMGN) Ascends While Market Falls: Some Facts to Note
by Zacks Equity Research
Amgen (AMGN) closed at $322.67 in the latest trading session, marking a +1.12% move from the prior day.
AMGN Stock Falls Despite Upbeat Data on Immunology Drugs: Here's Why
by Zacks Equity Research
Though Amgen reported encouraging results on two immunology drugs, Wall Street expresses skepticism as the data fell short when compared to existing treatments.
Regeneron Stock Down on Court Ruling for Amgen's Biosimilar of Eylea
by Zacks Equity Research
A federal judge rejected Regeneron's request for a preliminary injunction against Amgen in its lawsuit for Eylea's biosimilar.